Clinical Trial Update: Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002) [Phase 1]

View source ↗

Summary

Phase 1 trial update on safety, tolerability, and immunogenicity of the polyvalent pneumococcal conjugate vaccine V116 in Japanese adults; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infection

Drugs mentioned

• V116

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Pneumococcal Infection | Phase 1 | Status: COMPLETED | Results posted: 2023-07-07